Combined Therapy of Alfa-Interferon and Thymodulin on Children with Chronic Active Hepatitis B.
- Author:
Byung Ho CHOE
1
;
Cheolwoo KO
Author Information
1. Department of Pediatrics, Kyungpook National University School of Medicine,
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Chronic hepatitis B;
Interferon;
Thymodulin;
Children
- MeSH:
Child*;
DNA;
Follow-Up Studies;
Hepatitis;
Hepatitis B e Antigens;
Hepatitis B Surface Antigens;
Hepatitis B, Chronic;
Hepatitis, Chronic*;
Humans;
Interferons;
Thymosin
- From:Korean Journal of Pediatric Gastroenterology and Nutrition
1998;1(1):79-89
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Though many antiviral or immunomodulatory agents have been used in patients with chronic HBV hepatitis, interferon is considered to be the only effective therapeutic agent so far. Among immunomodulatory agents, thymodulin, the oral form of thymosin, is currently in clinical trial. We compared the efficacy of alfa-interferon therapy alone with a combined therapy of alfa-interferon and thymodulin in children with chronic active hepatitis B. METHOD: Twenty three children aged 4.4~13.7 years who were known to be positive for HBsAg and HBeAg in serum for at least 6 months and who had biopsy-proven chronic active hepatitis were given either combined therapy of alfa-interferon and thymodulin or alfa-interferon alone, and all children were HBV DNA positive in their serum at the beginning. Follow-ups have been done for at least 1 year after a 6 month course of therapy and clearance of viral replication markers has been evaluated. RESULTS: 1) During follow up period, 11 (48%) children were seroconverted to anti-HBe and were cleared of HBV DNA from their serum. However, 2 of them relapsed after discontinuance of interferon therapy. 2) Seroconversion occurred more frequently among those who had not been vertically transmitted, had elevated serum ALT levels and low HBV DNA levels before interferon therapy. 3) There was no significant advantage of the combined therapy with thymodulin compared to interferon therapy alone. CONCLUSION: Combined therapy of alfa-interferon and thymodulin failed to demonstrate synergistic effect. We think that combination therapies of alfa-interferon with other antiviral or immunomodulatory agents need to be studied in order to achieve better therapeutic responses.
